| Bevacizumab studied in …STUDIED_INderived200 of 1,821show all (up to 200) |
|---|
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 1,821 trials list this drug (445 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 1,821 trials list this drug (445 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06820463Phase 2 · recruiting A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997497Phase 3 · recruiting A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) · 1,821 trials list this drug (445 active) | — | — | Colon Adenocarcinoma,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222800Phase 3 · recruiting Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Neoplasm by Site,Digestive System Neoplasm,Intestinal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07346157Phase 1/Phase 2 · recruiting Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease · 1,821 trials list this drug (445 active) | — | — | Medulloblastoma,Childhood Medulloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07446322Phase 2 · recruiting FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · 1,821 trials list this drug (445 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07525206Phase 3 · recruiting A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756840Phase 2 · not yet recruiting Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) · 1,821 trials list this drug (445 active) | — | — | Respiratory System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843303Phase 2 · not yet recruiting Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647122Phase 1 · active not recruiting First in Human Study of AZD9592 in Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Head and Neck Neoplasm,Solid Neoplasm,Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06004245Phase 1 · recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06663319Phase 1 · recruiting A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers · 1,821 trials list this drug (445 active) | — | — | Digestive System Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06750094Phase 3 · recruiting A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy · 1,821 trials list this drug (445 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150208Phase 2 · recruiting T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198074Phase 3 · recruiting Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · 1,821 trials list this drug (445 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07216703Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) · 1,821 trials list this drug (445 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07271355Phase 3 · recruiting Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial · 1,821 trials list this drug (445 active) | — | — | Appendix Carcinoma,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07277270Phase 1 · recruiting A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07278336Phase 1 · recruiting A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07694427Phase 3 · not yet recruiting Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] · 1,821 trials list this drug (445 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05863195Phase 3 · recruiting Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial · 1,821 trials list this drug (445 active) | — | — | Colorectal Neoplasm,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · 1,821 trials list this drug (445 active) | — | — | Melanoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07722754Phase 2 · recruiting Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial · 1,821 trials list this drug (445 active) | — | — | Neoplasm,Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · 1,821 trials list this drug (445 active) | — | — | Malignant Peritoneal Neoplasm,Ovarian Neoplasm,Malignant Fallopian Tube Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824934Phase 1 · recruiting HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05489211Phase 2 · recruiting Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) · 1,821 trials list this drug (445 active) | — | — | Malignant Gastric Neoplasm,Malignant Biliary Tract Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221357Phase 2/Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05001880Phase 2 · recruiting Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · 1,821 trials list this drug (445 active) | — | — | Peritoneal Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445062Phase 1/Phase 2 · recruiting Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Malignant Digestive System Neoplasm,Colorectal Carcinoma,Malignant Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07059845Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07213804Phase 3 · recruiting A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Peritoneal Neoplasm,Fallopian Tube Neoplasm,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07728019Phase 2 · recruiting Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM · 1,821 trials list this drug (445 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833735Phase 1/Phase 2 · not yet recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040099Phase 2 · active not recruiting A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07111546Phase 2 · recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831187Phase 1/Phase 2 · not yet recruiting Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence · 1,821 trials list this drug (445 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06039202Phase 2 · suspended CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859762Phase 1 · recruiting A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318558Phase 3 · recruiting A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · 1,821 trials list this drug (445 active) | — | — | Ovarian Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01061515Phase 1 · active not recruiting Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797246Phase 2 · active not recruiting Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) · 1,821 trials list this drug (445 active) | — | — | Neoplasm,Squamous Cell Neoplasm,Papilloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798819Phase 3 · recruiting A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06233942Phase 1 · recruiting Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06311851Phase 1/Phase 2 · active not recruiting Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06427941Phase 1/Phase 2 · recruiting A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07823348Phase 3 · not yet recruiting JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974621Phase 2 · active not recruiting Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma · 1,821 trials list this drug (445 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05739981Phase 1/Phase 2 · recruiting Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05854498Phase 2 · recruiting Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908786Phase 1/Phase 2 · terminated A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07284849Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619235Phase 4 · recruiting A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819604Phase 2 · not yet recruiting Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03074513Phase 2 · active not recruiting Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Neuroendocrine Carcinoma,Peritoneal Malignant Mesothelioma,Pleural Malignant Mesothelioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04721132Phase 2 · active not recruiting Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482516Phase 3 · recruiting Evaluating Novel Therapies in ctDNA Positive GI Cancers · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma,Biliary Tract Adenocarcinoma,Gastric Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06787612Phase 2 · recruiting Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07816666Phase 3 · not yet recruiting Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929223Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06840002Phase 1/Phase 2 · recruiting A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843447Phase 1/Phase 2 · recruiting A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07381764Phase 2 · recruiting ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743164Phase 3 · not yet recruiting A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) · 1,821 trials list this drug (445 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01356290Phase 2 · recruiting Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04958811Phase 2 · active not recruiting Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC · 1,821 trials list this drug (445 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638852Phase 2 · recruiting Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. · 1,821 trials list this drug (445 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07775287Phase 3 · recruiting Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811271Phase 3 · not yet recruiting Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers · 1,821 trials list this drug (445 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07813572Phase 3 · not yet recruiting ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · 1,821 trials list this drug (445 active) | — | — | Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Adenosquamous Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02847559Phase 2 · completed Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma · 1,821 trials list this drug (445 active) | — | — | Anaplastic (Malignant) Meningioma,Meningioma,Grade 2 Meningioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06329570Phase 1/Phase 2 · suspended Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) · 1,821 trials list this drug (445 active) | — | — | Neoplasm,Glioblastoma,Glioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06625775Phase 1 · recruiting Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Malignant Lung Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06696768Phase 1 · recruiting Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890338Phase 2 · recruiting A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · 1,821 trials list this drug (445 active) | — | — | Fallopian Tube Neoplasm,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225270Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07549412Phase 3 · recruiting A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797283Phase 3 · not yet recruiting Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01746238Phase 1 · active not recruiting Bevacizumab/Doxorubicin/Radiation for Sarcoma · 1,821 trials list this drug (445 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02997228Phase 3 · active not recruiting Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study · 1,821 trials list this drug (445 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03715933Phase 1 · recruiting Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas · 1,821 trials list this drug (445 active) | — | — | Ewing Sarcoma,Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937830Phase 2 · active not recruiting Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07228832Phase 3 · recruiting Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05192798Phase 2 · recruiting Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC · 1,821 trials list this drug (445 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06400472Phase 1 · recruiting A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Ovarian Neoplasm,Pancreatic Neoplasm,Colorectal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07062055Phase 2 · recruiting BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07805551Phase 1/Phase 2 · recruiting A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178552Phase 2/Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) · 1,821 trials list this drug (445 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04524871Phase 1/Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) · 1,821 trials list this drug (445 active) | — | — | Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252649Phase 3 · recruiting Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06271837Phase 2 · active not recruiting A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824467Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06921785Phase 3 · recruiting Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684612Phase 3 · not yet recruiting A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) · 1,821 trials list this drug (445 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04374305Phase 2 · recruiting Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) · 1,821 trials list this drug (445 active) | — | — | Meningioma,Vestibular Schwannoma,Ependymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · 1,821 trials list this drug (445 active) | — | — | Hereditary Leiomyomatosis and Renal Cell Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05585814Phase 2 · active not recruiting CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05862285Phase 3 · recruiting A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791758Phase 1/Phase 2 · not yet recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma · 1,821 trials list this drug (445 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627635Phase 1/Phase 2 · active not recruiting FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm,Colon Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06294548Phase 1/Phase 2 · recruiting A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06576037Phase 1 · recruiting Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730750Phase 1/Phase 2 · active not recruiting A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564141Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791732Phase 3 · not yet recruiting A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01445509Phase 1 · completed Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07557251Phase 1 · recruiting A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00433511Phase 3 · active not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer · 1,821 trials list this drug (445 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00569127Phase 3 · active not recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor · 1,821 trials list this drug (445 active) | — | — | Neuroendocrine Neoplasm,Neuroendocrine Tumor,Neuroendocrine Tumor G2+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00588770Phase 3 · active not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · 1,821 trials list this drug (445 active) | — | — | Malignant Major Salivary Gland Neoplasm,Salivary Gland Carcinoma,Laryngeal Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00601900Phase 3 · completed Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer · 1,821 trials list this drug (445 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081262Phase 3 · active not recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · 1,821 trials list this drug (445 active) | — | — | Borderline Ovarian Mucinous Tumor,Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm,Primary Peritoneal Carcinoma,Adult Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 1,821 trials list this drug (445 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04449874Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06783647Phase 2 · recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07474727Phase 2 · recruiting A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00334815Phase 2 · active not recruiting Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery · 1,821 trials list this drug (445 active) | — | — | Lung Large Cell Carcinoma,Lung Squamous Cell Carcinoma,Lung Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00642603Phase 2 · terminated A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562028Phase 2 · completed BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) · 1,821 trials list this drug (445 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03133546Phase 2 · completed Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05281471Phase 3 · recruiting Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Ovarian Endometrioid Adenocarcinoma,Platinum-Resistant Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06313970Phase 2 · active not recruiting First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients · 1,821 trials list this drug (445 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00217737Phase 3 · completed Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer · 1,821 trials list this drug (445 active) | — | — | Colon Adenocarcinoma,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460767Phase 1 · active not recruiting Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma · 1,821 trials list this drug (445 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011550Phase 2 · suspended Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05775159Phase 2 · active not recruiting Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084481Phase 1 · recruiting Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 · 1,821 trials list this drug (445 active) | — | — | Esophageal Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01946529Phase 2 · completed Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors · 1,821 trials list this drug (445 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Desmoplastic Small Round Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797168Phase 1/Phase 2 · recruiting Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Lung Squamous Cell Carcinoma,Malignant Ovarian Neoplasm,Lung Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06011772early Phase 1 · active not recruiting EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07779538Phase 3 · not yet recruiting Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01792934NA · active not recruiting Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04008030Phase 3 · active not recruiting A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05636111Phase 1 · recruiting Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776171Phase 2 · not yet recruiting Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740165Phase 3 · completed Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) · 1,821 trials list this drug (445 active) | — | — | Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774247Phase 2 · not yet recruiting Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774611Phase 1/Phase 2 · not yet recruiting An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792695Phase 2 · recruiting A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07470853Phase 1 · recruiting A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. · 1,821 trials list this drug (445 active) | — | — | Platinum-Resistant Ovarian Carcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158258completed A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America · 1,821 trials list this drug (445 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05919264Phase 1/Phase 2 · recruiting FOG-001 in Locally Advanced or Metastatic Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Adamantinomatous Craniopharyngioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166406Phase 3 · recruiting Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03847428Phase 3 · active not recruiting Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083481Phase 1 · terminated A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01677884Phase 2 · completed Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy · 1,821 trials list this drug (445 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02217956Phase 1 · completed Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma · 1,821 trials list this drug (445 active) | — | — | Primary Peritoneal Carcinoma,Fallopian Tube Adenocarcinoma,Ovarian Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02971501Phase 2 · active not recruiting Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases · 1,821 trials list this drug (445 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211323Phase 2 · active not recruiting A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer · 1,821 trials list this drug (445 active) | — | — | Combined Hepatocellular Carcinoma and Cholangiocarcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07042802Phase 1/Phase 2 · recruiting A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06139211Phase 1/Phase 2 · completed A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06543576Phase 1/Phase 2 · recruiting External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer · 1,821 trials list this drug (445 active) | — | — | Cervical Adenocarcinoma,Cervical Squamous Cell Carcinoma,Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02884648Phase 2 · active not recruiting Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery · 1,821 trials list this drug (445 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068610Phase 1/Phase 2 · active not recruiting COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC · 1,821 trials list this drug (445 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04837716Phase 1 · active not recruiting Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07071714Phase 2 · active not recruiting A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07420439Phase 2 · not yet recruiting Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07074756NA · recruiting A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial · 1,821 trials list this drug (445 active) | — | — | Glioblastoma,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00265850Phase 3 · completed Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02761070Phase 3 · completed Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III · 1,821 trials list this drug (445 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06580314Phase 3 · recruiting Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer · 1,821 trials list this drug (445 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01837862Phase 1/Phase 2 · active not recruiting A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas · 1,821 trials list this drug (445 active) | — | — | Anaplastic Astrocytoma,Glioblastoma,Glioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02519348Phase 2 · active not recruiting A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04356729Phase 2 · active not recruiting A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma · 1,821 trials list this drug (445 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04999761Phase 1 · recruiting AB122 Platform Study · 1,821 trials list this drug (445 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05579366Phase 1/Phase 2 · recruiting Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) · 1,821 trials list this drug (445 active) | — | — | Malignant Mesothelioma,Primary Peritoneal Carcinoma,Breast Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06908031Phase 2 · completed SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer · 1,821 trials list this drug (445 active) | — | — | Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07737600Phase 1/Phase 2 · not yet recruiting A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07179900Phase 2 · recruiting Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03141684Phase 2 · active not recruiting Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma · 1,821 trials list this drug (445 active) | — | — | Alveolar Soft Part Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05063552Phase 2/Phase 3 · active not recruiting Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers · 1,821 trials list this drug (445 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Malignant Sinonasal Neoplasm,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03526432Phase 2 · active not recruiting Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464030Phase 1 · active not recruiting Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04245085Phase 2 · completed ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974944Phase 2 · terminated First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05284643NA · recruiting Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma · 1,821 trials list this drug (445 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04743661Phase 2 · active not recruiting 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma · 1,821 trials list this drug (445 active) | — | — | Medulloblastoma,Ependymoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07059494Phase 4 · recruiting Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07479485Phase 1/Phase 2 · recruiting MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) · 1,821 trials list this drug (445 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527858Phase 2 · recruiting Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03203525Phase 1 · terminated Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03181100Phase 2 · active not recruiting Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer · 1,821 trials list this drug (445 active) | — | — | Thyroid Gland Anaplastic Carcinoma,Thyroid Gland Carcinoma,Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768063Phase 3 · active not recruiting A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study · 1,821 trials list this drug (445 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04776655Phase 3 · active not recruiting Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07094893Phase 4 · not yet recruiting Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02821559Phase 2 · completed Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05719558Phase 1 · recruiting A Study of ASP1002 in Adults for Treatment of Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05836324Phase 1 · recruiting A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors · 1,821 trials list this drug (445 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07500298Phase 1 · recruiting Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03762018Phase 3 · completed BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · 1,821 trials list this drug (445 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |